Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
In this pharmacokinetic/pharmacodynamic modelling study we will determine the ability of
intranasal and intramuscular naloxone to reverse opioid (fentanyl and sufentanil)- induced
respiratory depression in healthy volunteers and chronic opioid users to develop dosing
recommendations in case of opioid-induced respiratory depression from an opioid overdose in
clinical practice and in the out-of-hospital overdose.